Press Releases for ALO

Press Releases
Alstom Announces Appointment of North American Executives
U.S. Federal Trade Commission Provisionally Accepts Consent Decree and Terminates Waiting Period for King Pharmaceuticals’ Acquisition of Alpharma
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Zacks #1 Rank Top Performers: American Science and Engineering, Allegiant Travel, Alpharma, Hanger Orthopedic and Emergency Medical Services
DURECT's Collaboration With Alpharma Clears HSR Review and Is Effective
Alpharma Reports Third Quarter 2008 EPS of $0.10
Alpharma Announces Information for Third Quarter 2008 Earnings Conference Call
Zacks Analyst Blog Highlights: Johnson & Johnson, CarMax, Inc., Rackable Systems, Inc., DURECT Corp. And Alpharma Inc.
National Family Partnership Designates October 27th 'Lock Your Meds' Day
King Pharmaceuticals Extends Tender Offer to Acquire Alpharma
Alpharma Board of Directors Unanimously Rejects King Pharmaceuticals' Unsolicited Tender Offer as "Financially Inadequate"
Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
Alpharma Licenses Durect's Novel Bupivacaine Patch
King Commences Cash Tender Offer for Alpharma at $37 Per Share
Alpharma Urges Shareholders to Take No Action with Respect to King Pharmaceuticals' Announced Intent to Commence a Tender Offer
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
Alpharma Adopts Limited Duration Shareholder Rights Plan
Alpharma Announces Acceptance of the EMBEDA(TM) Capsule NDA Filing
Alpharma Responds to Unsolicited Proposal by King Pharmaceuticals, Inc.
Zacks Bull and Bear of the Day Highlights: Churchill Downs, Alpharma, Magellan Midstream Partners, News Corp. And Hartford Financial Services
Alpharma Reports Second Quarter 2008 Revenue Growth of 25% From Continuing Operations
Alpharma Announces Information for Second Quarter 2008 Conference Call
Alpharma Announces the Resubmission of a New Drug Application for EMBEDA(TM) Capsules
Alpharma to Present at Jefferies 2nd Annual Healthcare Conference
Alpharma Announces Changes to Executive Leadership Team
Alpharma to Present at Goldman Sachs Annual Healthcare Conference
Alpharma Files Form 10-Q for the Three Months Ended March 31, 2008 - Jun 1 2008 7:07AM
Alpharma to Present at Bank of America Healthcare Conference - Jun 1 2008 7:07AM
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session - Jun 1 2008 7:07AM
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions - Jun 1 2008 7:07AM
Alpharma Reports First Quarter 2008 Revenue Growth of 33% From Continuing Operations - Jun 1 2008 7:06AM
European Capital Invests Euro 142 Million and Supports Growth in Buyout Investments in Q1 2008 - Jun 1 2008 6:30AM
Alpharma Announces Information for First Quarter 2008 Earnings Conference Call
Alpharma to Present at Morgan Stanley Global Healthcare Unplugged Conference
Alpharma to Withdraw and Resubmit Its New Drug Application for EMBEDA(TM)
European Capital's Sponsor Finance Group Invests Euro 97 Million in Three Portfolio Companies
Alpharma Announces Updated Financial Outlook for 2008
Alpharma Schedules Conference Call to Update Financial Outlook for 2008
Alpharma Completes Sale of Active Pharmaceutical Ingredients Business